TABLE 3.
Neutralization properties of SHIV-SF162p3 WT, SHIV-AE16 W, and SHIV325c H challenge stocksa
| Specificity | Antibody | SF162p3 Parental | SF162p3S | AE16 Parental | AE16W | 325c Parental | 325cH |
|---|---|---|---|---|---|---|---|
| CD4bs | shuCD4 | 16.26 | 12.77 | 24.67 | 6.08 | >50 | 5.824 |
| 3BNC117 | >50 | 0.48 | >50 | >50 | >50 | 47.016 | |
| VRC01 | 1.08 | 0.57 | >50 | >50 | >50 | 43.044 | |
| b12 | 2.39 | 2.42 | >50 | >50 | >50 | >50 | |
| N6 | 0.25 | 0.13 | 1.67 | 2.70 | 9.3 | 8.097 | |
| V1/V2 | PG9 | >50 | >50 | 0.04 | 0.05 | 1.727 | 1.612 |
| PG16 | >50 | >50 | <0.023 | <0.023 | <0.023 | 0.039 | |
| PGDM1400 | >50 | >50 | <0.023 | <0.023 | <0.023 | <0.023 | |
| CAP256-VRC25.26 | >50 | >50 | <0.023 | <0.023 | <0.023 | <0.023 | |
| V3 glycan | 10-1074 | 0.04 | <0.023 | >50 | >50 | >50 | >50 |
| PGT121 | <0.023 | <0.023 | >50 | >50 | >50 | >50 | |
| PGT128 | 0.37 | 0.10 | >50 | >50 | >50 | >50 | |
| MPER | 2F5 | >50 | >50 | 36.12 | 13.30 | >50 | >50 |
| 4E10 | >50 | >50 | 18.74 | 7.19 | >50 | >50 | |
| 10E8 | 12.22 | 3.13 | 1.22 | 1.26 | 44.792 | 22.583 | |
| HIV+ serum | HIV-018 | <20 | <20 | <20 | <20 | <20 | <20 |
| HIV-019 | <20 | <20 | <20 | <20 | <20 | <20 | |
| HIV-021 | <20 | <20 | <20 | <20 | <20 | <20 | |
| HIV-024 | 161 | 290 | <20 | <20 | <20 | <20 | |
| HIV-025 | <20 | <20 | <20 | <20 | <20 | <20 |
a
Assays were conducted in TZM-bl cells. Values given are neutralization titers (50% inhibitory concentrations).